Business
Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition
Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival (PFS) of 22.1 months across all doses tested Emerging data from randomized Phase 1b cohorts points to higher ORR and longer progression free survival at the 600 mg recommended Phase 2 dose (RP2D) compared to the 200 mg dose Bexobrutideg was well tolerated with a consistent safety profile between the 600 mg RP2D and the overall study population Phase 2 clin
About this update from Nurix Therapeutics, Inc.
[{"type":"image","alt":"Nurix Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Nurix Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":124,"height":59,"url":"https://media.zenfs.com/en/globenewswire.com/d4426df492fc50ab857f27928363f9ff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GUPiZSd9EAPs2S1gR73bqw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEwMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d4426df492fc50ab857f27928363f9ff","width":124,"height":59}},"lazy":false},{"type":"text","content":"Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival (PFS) of 22.1 months across all doses tested","length":186,"tagName":"p"},{"type":"text","content":"Emerging data from randomized Phase 1b cohorts points to higher ORR and longer progression free survival at the 600 mg recommended Phase 2 dose (RP2D) compared to the 200 mg dose","length":178,"tagName":"p"},{"type":"text","content":"Bexobrutideg was well tolerated with a consistent safety profile between the 600 mg RP2D and the overall study population","length":121,"tagName":"p"},{"type":"text","content":"Phase 2 clinical trial of bexobrutideg (DAYBreak-CLL-201) currently enrolling globally","length":86,"tagName":"p"},{"type":"text","content":"Company will host a webcast to discuss the data on Monday, December 8, 2025, at 8:15 p.m. ET ","length":92,"tagName":"p"},{"type":"text","content":"BRISBANE, Calif., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced new clinical data from the Company’s ongoing Phase 1a/1b NX-5948-301 study of bexobrutideg (NX-5948) in patients with relapsed or refractory B-cell malignancies. These data will be presented in an oral session at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, FL, on December 6, 2025, at 9:45 a.m. ET, by Zulfa Omer, M.D., Assistant Professor of Internal Medicine at the University of Cincinnati and a principal investigator in the study.","length":769,"tagName":"p"},{"type":"text","content":"“The clinical activity and durability observed with bexobrutideg ...